



Special Diabetes Program for Indians (SDPI)

Get Ready for the SDPI 2022 Competitive Application Process

IHS Division of Diabetes Treatment and Prevention
January 27, 2021

Abbreviations

- AI/AN = American Indian/Alaska Native
- ADC = Area Diabetes Consultant
- AOR = Authorized Organization Representative
- DDTP = IHS Division of Diabetes Treatment and Prevention
- DGM = IHS Division of Grants Management
- DTLL = Dear Tribal Leader Letter
- DUIOLL = Dear Urban Indian Organization Letter
- DUNS = Data Universal Numbering System
- IHS = Indian Health Service
- MOA = Memorandum of Agreement
- NOFO = Notice of Funding Opportunity (also known as FOA)
- ORC = Objective Review Committee
- SAM.gov = System for Award Management
- SDPI = Special Diabetes Program for Indians
- TLDC = Tribal Leaders Diabetes Committee
- UIO = Urban Indian Organization



Purpose of this Webinar

- Help SDPI grantees prepare for the 2022 Competitive Application process.
 - Introduce the competitive application process
 - Introduce competitive application process terminology
 - Provide steps that grantees can do now to prepare for the competitive application process.
 - Preview future tasks for the competitive application process.

SDPI Overview

- In response to rising rates of diabetes in AI/AN people, Congress established SDPI in the Balanced Budget Act of 1997 (P.L. 105-33)
 - “The Secretary shall make grants for providing services for the prevention and treatment of diabetes...” (42 USC 254c-3)
- Today SDPI provides funds to 301 I/T/U grant programs in 35 states for diabetes prevention and treatment
 - Tribal 233 (+21 sub-grantees)
 - Urban 29
 - IHS 13 (+5 sub-grantees)

Current SDPI Project Period

- SDPI is in the 6th year of a 6-year project period (also known as a grant cycle), made up of 6 budget periods:
 - 2016: January 1, 2016 – December 31, 2016
 - 2017: January 1, 2017 – December 31, 2017
 - 2018: January 1, 2018 – December 31, 2018
 - 2019: January 1, 2019 – December 31, 2019
 - 2020: January 1, 2020 – December 31, 2020 (extension approved)
 - **2021: January 1, 2021 – December 31, 2021**

SDPI 2021 Funding and NoA Update

SDPI 2021 Funding and NoA Update

- SDPI FY 2021 Funding:
 - CARES Act: \$25 million
 - Initial FY 2021 Continuing Resolution (thru 12/11): \$4.5 million
 - 1-week Continuing Resolution (thru 12/18)
 - **Coronavirus Response and Relief Act, 2021, which includes funding for SDPI at the current \$150 million/year for 3 years: fiscal years (FY) 2021, 2022, and 2023!**
- So far, IHS has *received* approximately \$29.5 million for SDPI FY 2021, which is 20% of the usual \$150 million.
- In order to maximize existing funds and to issue the NoAs as timely as possible, the IHS Division of Grants Management (DGM) is utilizing a combination of:
 1. **\$29.5 million** of SDPI FY 2021 authorized funds,
 2. **\$30 million** in SDPI FY 2020 offset and prior year funds, as well as
 3. **Funding from offsets** implemented in FY 2021 to 78 SDPI grants with large unobligated (carryover) balances.

SDPI FY 2021 NoAs

- **Awards without Offsets:** Awards not receiving an offset have/will receive a NoA for approximately 55% of the annual award amount. When the funds Congress just authorized become available, these awards will be amended to provide the remaining 45% of their annual award amount.
- **Awards with Offsets:** An offset authorizes funding levels for an award but where some/all of those funds utilize the grant's own unobligated balances. As such, the 78 grants receiving an offset in FY 2021 have/will receive a NoA granting authority to utilize their own unobligated funding for 50-100% of their annual grant award, depending on the size of each grant's offset.

SDPI FY 2021 NoAs: Awards with Offsets

- Grants receiving a **100% offset** have/will receive a NoA for their full annual grant amount utilizing their own unobligated funds (including \$1 in new funds necessary to keep their Payment Management System accounts active).
- Grants receiving **offsets of 50% or 75%** have/will receive a NoA for either 50% or 75% of their annual grant amount utilizing their own unobligated funds (including \$1 in new funds).
 - Once the funds Congress just authorized become available, these awards will be amended to provide the remaining 50% or 25% of their annual grant amount.

Contact Info: DGM

- IHS Division of Grants Management
 - Website: www.ihs.gov/dgm
 - Main line: 301-443-0243

IHS Division of Grants Management – Grants Management Specialists (GMS)

IHS Area	GMS	GMS Email	GMS Phone
Albuquerque, Nashville, Navajo, Phoenix, Tucson	John Hoffman	John.hoffman@ihs.gov	301-443-2116
Great Plains, Portland, Oklahoma City	Cherron Smith	Cherron.smith@ihs.gov	301-443-2192
Alaska, Bemidji, Billings	Patience Musikikongo	Patience.musikikongo@ihs.gov	301-443-2059
California and Urban	Pallop Chareonvootitam	Pallop.chareonvootitam@ihs.gov	301-443-2195



**The SDPI Application for 2022 will
be a Competitive Process as it
begins a new Grant Cycle
(2022 – 2026)**

About Competitive Process

- Applicants do **NOT** compete against one another.
- For SDPI, the competition is to achieve a fundable score (60 out of a possible 100 points) in the objective review process.
- **All eligible applicants who submit a complete application and achieve a fundable score in objective review will receive funding.**
- Essential to submit a complete application by the due date!
- A Competitive Process begins with a **Notice of Funding Opportunity (NOFO)**.

Notice of Funding Opportunity (NOFO)

- **NOFO** - Provides a description of the project and the entities that are eligible to apply.
 - Found in the Federal Register
- After 1997, NOFOs for SDPI were released for grant cycles which began in 2004, 2010, and 2016.
- The SDPI 2022 NOFO and application packet will be released sometime this spring (April or May).
- DDTP will send an email announcement when the NOFO is released.

SDPI Timeline

- 2022 NOFO and Application available: **Spring 2021**
- 2022 Applications due: **End of Summer 2021**
- Objective Review Committee (ORC) Process: **Fall 2021**
- Notices of Award Distributed: **December 2021**

About Objective Review Committee (ORC) Process

- **ORC Process** - applications that pass screening are peer reviewed by a panel of at least three people, who assess and score each application independently. Then, the peer review panel will convene to discuss the merits of the applications. A series of policies and assurances are in place to maintain a fair, objective process based on material facts in the applications and without conflicts of interest (COI) for the peer reviewers. The federal agency staff monitor and participate in this review.

Application Processes (a visual)

Continuation Application



Competitive Process



What to do NOW to prepare for the Competitive Application Process

- Items to check with your organization's grant/financial office NOW:
 1. **DUNS Registration:** Ensure your organization's DUNS registration is current.
 2. **SAM.gov:** Ensure your organization's SAM.gov is current.
 3. **AOR:** Ensure your organization has an Authorized Organization Representative (AOR) and make sure they can submit the SDPI application. Also keep track of your AOR.
 4. **Grants.gov:** Ensure your organization is registered in Grants.gov.
 - Grants.gov is the site used to submit competitive applications.
- All current grantees had these in place to apply for and receive an SDPI grant for the 2016 grant cycle
 - Please be sure that these are now (and remain) up-to-date throughout the 2022 application process!

What to do NOW: DUNS Registration

1. Ensure your organization's **DUNS** registration is current.
 - Data Universal Numbering System (DUNS) Number is a nine-digit number established and assigned by Dun and Bradstreet, Inc. (D&B) to uniquely identify entities. A non-Federal entity is required to have a DUNS number in order to apply for, receive, and report on a Federal award.
 - This information may already be available in your organization's grant or financial office.
 - Work with your organization's grant/financial office to ensure that your organization has a DUNS.
 - A DUNS number may be obtained from D&B by telephone (currently 866–705–5711) or the Internet (currently at <https://www.dnb.com/>).
 - Estimated timeline for this process: 1 – 2 Business Days

What to do NOW: SAM.gov registration

2. Ensure your organization's SAM.gov registration is current.

- SAM = System for Award Management
- Organizations need to have active SAM.gov certifications and accounts in order to receive an SDPI award.
 - Work with your organization's grant/financial office to ensure that your organization has a current SAM.gov registration.
 - There have been recent changes to the process—be sure to check
- Questions about SAM.gov entity registration and renewal can only be answered by [SAM.gov](https://sam.gov) customer support.

What to do NOW: AOR and Grants.gov

3. Ensure your organization has an **Authorized Organization Representative (AOR)** and make sure they can submit the SDPI application. Also keep track of your AOR.

- The AOR is a member of your organization authorized to submit applications in Grants.gov on behalf of the organization.
- If there is turnover, find out who will be the next AOR.

4. Ensure your organization is registered in **Grants.gov**.

- Competitive applications will be submitted through Grants.gov (*not* GrantSolutions)
- Helpful information and resources are available on the [Grants.gov](https://www.grants.gov) site.

What to do NOW to prepare for the Competitive Application Process

5. Review your 2016 and 2021 Applications

- Both applications can be found in GrantSolutions (look at grant history and grant notes).
- Your 2016 application is the last application your program submitted during a **competitive** process.
- Your 2021 application is the latest **continuation** application that your program submitted.
- Note similarities and differences in questions asked and changes in your program plan over the years.

What to do NOW to prepare for the Competitive Application Process

6. Plan to attend **training** opportunities offered by DDTP, DGM, your ADC

- Upcoming Trainings offered by DDTP will be available on the [SDPI Training webpage](#).
- DGM offers trainings and resources on their [policy training tools webpage](#).
 - DGM may also be special guest presenters on upcoming DDTP Trainings – stay tuned!
- Stay in touch with your [ADC](#) for any trainings they may offer.



Coming Attractions (Spring 2021): NOFO and Application Packet



When the SDPI NOFO Becomes Available (Spring 2021)

- Carefully read through the NOFO
 - The NOFO will provide a description of the project and the entities that are eligible to apply.
 - The objective review criteria will also be provided.
- **Note the application due date**
 - Plan to submit your application **early** (at least several weeks before the application due date).
 - If you submit early, your organization will have a chance to rectify problems/errors (as long as this is done by the due date).
- DDTP, DGM, and ADCs will provide training and technical assistance both before and after the NOFO is released.
 - *But won't be able to assist with writing individual applications*

When the Application Becomes Available (Spring 2021)

- Download the **application package** from Grants.gov
- **Note the application due date**
 - Plan to submit your application early (at least several weeks before the application due date).
 - If you submit early, your organization will have a chance to rectify problems/errors (as long as this is done by the due date).
- Additional application information will available on the SDPI [Application/Reports webpage](#).
- DDTP will send out an email when the application becomes available.

ORC Application Reviewers Will Be Needed!

- ORC application reviewers will be needed this fall, after the applications are due
- It's important to have SDPI grantees involved in the ORC process!
 - For the last SDPI competitive process in 2015, most reviewers were SDPI grantee staff.
 - **Consider getting involved in this year's ORC process as an application reviewer!**
- DDTP will send out an email when information is available about signing up to be an ORC reviewer.

Resources

- [SDPI website](#)
 - Check often for grant updates and upcoming webinars
 - [SDPI Training webpage](#)
- [Grants.gov Website](#)
 - Registration Information, competitive application process resources
 - Steps to [register your organization](#)
- [Division of Grants Management](#)
 - [policy training tools webpage](#)

Stay in Touch

- SDPI Grantee email list
 - send a request to be added to sdpi@ihs.gov
 - Emails will provide latest updates, webinars, and resources.
- [ADC Directory](#)
 - Stay in touch with your ADC for guidance and local training opportunities/resources.
- [Division of Grants Management/Grants Management Specialist](#)
 - May provide further guidance on the competitive application process.

Free resources from DDTP!

- [Diabetes Education Lesson Plans \(9 topics\)](#) - These lesson plans offer culturally relevant materials that are adaptable for individual or group sessions and can complement existing diabetes education curricula.



- [Treatment Algorithms \(6 topics\)](#) – Concise information for point of care reference. Print or view online or on a mobile device.

Glucose Management in Type 2 Diabetes

Please Note: This algorithm is not intended for treatment and target selection in children or in women who are or could become pregnant.

Step 1: Determine Individualized A1C Target Range
Select based on age, duration of diabetes, patient preference, comorbidities, hypoglycemia risk, and other factors.

Major Comorbidity	Microvascular Complications		
	Absent or Mild	Moderate	Advanced
Absent (and/or >10-15 years of life expectancy)	6.0-7.0%	7.0-8.0%	7.5-8.5%
Present (and/or 5-10 years of life expectancy)	7.0-8.0%	7.5-8.5%	7.5-8.5%
Marked (and/or <5 years of life expectancy)	8.0-9.0%	8.0-9.0%	8.0-9.0%

Major comorbidity includes but is not limited to significant CVD, recent stroke, life-threatening malignancy, or severe CKD, COPD, or chronic liver disease. Microvascular disease: retinopathy, neuropathy, or CKD. Adapted from the [VA/DoD Management of Diabetes Mellitus Guideline](#).

↓ If A1C not within individualized target range

Step 2: Initiate Medication Therapy
If significant weight loss or ketonuria, use insulin (hospitalize if acidotic). Otherwise:
Start metformin if A1C above patient's target but <9%.
Start metformin and a second medication if A1C ≥9% (see Step 3).

↓ If A1C not within individualized target range

Step 3: Increase Dosage(s) and/or Add Another Medication
Select additional medication(s) based on formulary options, side effects, cost, comorbidities (e.g., CVD), medication regimen complexity, and patient preference.

Medication	Weight	A1C	Risk of Hypoglycemia	Cost
Metformin	- to ↓	↓↓	—	\$
DPP-4 Inhibitor	-	↓	-	\$\$
GLP-1 Receptor Agonist	↓↓	↓↓	-	\$\$\$
Insulin	↑↑ to ↑↑↑	↑↑↑	↑↑↑	\$\$ to \$\$\$
SGLT2 Inhibitor	↓	↓	-	\$\$\$
Sulfonylurea	↑↑	↓↓	↑↑	\$
Thiazolidinedione	↑	↓↓	-	\$

Do not use GLP-1 Receptor Agonist and DPP-4 inhibitors together as no A1C benefit.

© IHS Division of Diabetes Treatment and Prevention

Glucose Management in Type 2 Diabetes

Metformin
Monitor and supplement vitamin B12 as needed with long term use. Discontinue if eGFR <30ml/min/1.73m².
Warning: May cause lactic acidosis (rare).
Start 500mg daily with meals and increase no faster than 500mg/day each week. If GI symptoms occur, may increase more slowly.
Max dose: Regular release tablets: 2,550mg divided BID or TID. XR tablets: 2,000mg daily or divided BID.

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors*
Alogliptin (Nesina®) Start 25mg daily. May increase risk of heart failure.
Sitagliptin (Januvia®) Start 100mg daily.
Linagliptin (Tradjenta®) Start 5mg daily.
Saxagliptin (Onglyzon®) Start 2.5-5mg daily. May increase risk of heart failure.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
GI side effects common.
Warning: May increase risk of thyroid tumor.
Dulaglutide (Trulicity®) Start 0.75mg SC weekly. May increase to 1.5mg/week.
Esemotide ER (Bydureon®) Start 2mg SC weekly.*
Liraglutide (Victoza®) Start 0.6mg SC daily.
Increase to 1.2mg daily in 1 week. May increase to 1.8mg daily.
Indicated to reduce the risk of CV events in patients with established CVD.
Semaглутиде (Ozempic®) Start 0.25mg SC weekly for 4 weeks, then increase to 0.5mg weekly for 4 weeks. May increase to 1mg weekly.

Insulin - See [Insulin Therapy Algorithm](#)

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors*
May cause volume depletion, orthostatic hypotension, genital fungal infections, DKA, acute kidney injury, and UTI.
Canagliflozin (Invokana®) Start 100mg daily before first meal. May increase to 300mg daily.
Warning: May increase risk of lower limb amputations.
Indicated to reduce the risk of CV events in patients with established CVD.
Empagliflozin (Jardiance®) Start 10mg daily. May increase to 25mg daily.
Indicated to reduce the risk of CV death in patients with established CVD.

Sulfonylureas
May cause hypoglycemia, weight gain.
Glibenclamide Start 2.5-5mg daily - max 20mg BID. ER formulation dosed 5-20mg daily.
Glimepiride Start 1-2mg daily - max 8mg daily.

Thiazolidinedione (TZD)
May increase risk of bone fracture. Do not use in patients with bladder cancer. Check LFTs before starting. May cause weight gain.
Warning: Increased risk of heart failure.
Pioglitazone (Actos®) Start 15mg daily, may increase to 30-45mg daily.
Max A1C changes may take up to 12 weeks to occur.

* See prescribing reference when eGFR <60ml/min/1.73m². Medications on the IHS National Core Formulary are in **BOLD** above.
Please consult a complete prescribing reference for more detailed information. This is a summary of the most commonly ordered non-insulin diabetes medications and drug classes from the IHS National Supply Service Center. No endorsement of specific products is implied.

Last updated March 2019





Questions?

Type questions in the box below titled
“Enter Questions Here!”

Thank you

www.ihs.gov/diabetes/

www.ihs.gov/sdpi/

Upcoming SDPI Webinars



Date	Time	Topic
Wednesday February 24, 2021	3-4pm ET (2 CT / 1 MT / 12 PT / 11 AKT)	Optional Webinar SDPI Basics
Tuesday March 30, 2021	3-4pm ET (2 CT / 1 MT / 12 PT / 11 AKT)	Optional Webinar Planning, Implementation, Evaluation (PIE) and SDPI

All upcoming webinars also available on [SDPI Training](#) webpage.